Abstract
Background Life expectancy can be estimated accurately from a cohort of individuals born in the same year and followed from birth to death. Due to the difficult and time-consuming nature of following a cohort prospectively, life expectancy is often assessed based on death data, which may lead to potentially biased estimates. This is more likely to be a problem in rare diseases such as Morquio syndrome A.
Method To investigate how accurate the estimation of life expectancy is using death data, we simulate the survival of individuals with Morquio syndrome A under four different survival scenarios. In each scenario, we estimate the mean and median survival times within a defined period and compare them with the true life expectancy.
Results When life expectancy is constant during the entire period, using death data does not result in a biased estimate of life expectancy. However, when life expectancy increases during the follow-up period, using only death data leads to a substantial underestimation of life expectancy.
Conclusion Life expectancy can change over time, along with changes in the environment and/or biomedical innovation. When the life expectancy is increasing — as is often expected to be the case in rare diseases — estimating it based on contemporary death data will result in a downward bias. Therefore, it is crucial to understand how estimates of life expectancy are obtained and to interpret them in an appropriate context, and to assess estimation methods within a sensitivity analysis framework, similar to the simulations performed herein.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was performed as part of a student MS project at Georgetown University. No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used deidentified publicly available data, hence there was no need for IRB approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The dataset we used had previously been published in: C. Lavery and C. Hendriksz. Mortality in Patients with Morquio Syndrome A. JIMD Reports, 15, 2014.
https://link.springer.com/chapter/10.1007/8904_2014_298
https://github.com/xueyin97/Bias-estimating-life-expectancy-Morquio